Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach

Mehmet Ozcan, Ozlem Altay, Simon Lam, Hasan Turkez, Yasemin Aksoy, Jens Nielsen, Mathias Uhlen, Jan Boren, Adil Mardinoglu*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death primarily due to the lack of effective targeted therapies. Despite the distinct morphological and phenotypic patterns of HCC, treatment strategies are restricted to relatively homogeneous therapies, including multitargeted tyrosine kinase inhibitors and immune checkpoint inhibitors. Therefore, more effective therapy options are needed to target dysregulated metabolic and molecular pathways in HCC. Integrative genomic profiling of HCC patients provides insight into the most frequently mutated genes and molecular targets, including telomerase reverse transcriptase, the TP53 gene, and the Wnt/β-catenin signaling pathway oncogene (CTNNB1). Moreover, emerging techniques, such as genome-scale metabolic models may elucidate the underlying cancer-specific metabolism, which allows for the discovery of potential drug targets and identification of biomarkers. De novo lipogenesis has been revealed as consistently upregulated since it is required for cell proliferation in all HCC patients. The metabolic network-driven stratification of HCC patients in terms of redox responses, utilization of metabolites, and subtype-specific pathways may have clinical implications to drive the development of personalized medicine. In this review, the current and emerging therapeutic targets in light of molecular approaches and metabolic network-based strategies are summarized, prompting effective treatment of HCC patients.

Original languageEnglish
Article number2000030
JournalAdvanced Biosystems
Volume4
Issue number6
DOIs
Publication statusPublished - 1 Jun 2020

Keywords

  • genome scale metabolic models
  • hepatocellular carcinoma
  • molecular‑targeted therapies
  • network-driven stratification
  • systemic therapies

Fingerprint

Dive into the research topics of 'Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach'. Together they form a unique fingerprint.

Cite this